Charles Schwab’s Cocrystal Pharma COCP Stock Holding History

Charles Schwab’s Portfolio COCP Stock Details COCP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-3,270	Closed	-$50K	–	3512
2021 Q2	$50K	Buy	+3,270	New	+$49.7K	﹤0.01%	3369

Other funds holding COCP

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Mariner Overland Park, Kansas $85.7B AUM 24.21% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Charles Schwab's COCP Position: Q3 2021 in Review

Charles Schwab sold out of Cocrystal Pharma (COCP) in Q3 2021, closing a stake of 3,270 shares — an estimated $50K sold.

Charles Schwab first reported a position in COCP in Q2 2021 and held it in 1 quarter. The position peaked at $50K in Q2 2021. 41 funds tracked by Wall St. Rank hold COCP as of Q3 2021.

Charles Schwab reported no remaining Cocrystal Pharma position as of Q3 2021 after selling out during the quarter.
Charles Schwab sold 3,270 Cocrystal Pharma shares in Q3 2021, an estimated $50K.
Charles Schwab first reported a position in Cocrystal Pharma in Q2 2021 and held it in 1 quarter.
Charles Schwab's Cocrystal Pharma position peaked at $50K in Q2 2021.
41 funds tracked by Wall St. Rank held Cocrystal Pharma as of Q3 2021.

Based on Charles Schwab's 13F filing for Q3 2021, filed 16 Nov 2021.